Letters of intent (LOI’s) are sought for preclinical and/or clinical studies from academic or industry applicants with innovative approaches to modulate the immune response of the host to reduce or eliminate:
- the fibrotic response to implanted materials, and
- the immune response to implanted cells.
Only projects with relevance to T1D will be considered.
Examples of research appropriate for this RFA include, but are not limited to:
- Bioactive coatings and surface treatments of implant surfaces to reduce the fibrotic response and induce graft tolerance (e.g. extracellular matrix or basement membrane mimetic coatings, tethering of immune cell signaling ligands);
- The use of nanocomposite materials for controlled combinatorial localised delivery of drugs and tolerogenic factors;
- Technologies for in vivo reprogramming of immune cells for induction of tolerogenic phenotypes to achieve antigen-specific tolerance (e.g. novel tolerogenic nanoparticle formulations, artificial antigen-presenting cells (aAPC));
- Technologies for eliminating antigen-specific effector cells or rendering them unreactive (e.g. killer aAPCs);
- Testing of candidate immunotherapies in low burden regimens to enhance graft longevity and survival.
Funding & Duration
Strategic Research Agreement applications may request up to USD $200,000 (approx. AUD $272,000) per year (including up to 10% indirect costs) for up to 2 years.
Pilot and Feasibility studies without significant preliminary data may be submitted and can request up to total USD $150,000 (approx. AUD $204,000) per year for one year (including 10% indirect costs).
Applicants for SRA’s must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent and have a faculty position or equivalent at a college, university, medical school, or other research facility.
Applications from for-profit entities or industry collaborations with academia may be submitted to this LOI, however additional information will be requested from for-profit entities if a full application is invited.
For clinical studies, applicants must hold an appointment or joint appointment in a subspecialty of clinical medicine, and conduct human clinical research.
To assure continued excellence and diversity among applicants and awardees, JDRF welcomes proposals from all qualified individuals and encourages proposals from persons with disabilities, women, and members of minority groups underrepresented in the sciences.
There are no citizenship requirements for this program.
Submission Requirements & Due Dates
- 27 September 2018 – Letter of Intent (LOI) submitted to Sponsor
- 8 November 2018 – full applications submitted for internal review.
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review